Innovation

NEW YORK & GREENWOOD VILLAGE, Colo.--(BUSINESS WIRE)-- ANANDA Scientific Inc., a research focused biopharmaceutical company today announced approval by the US Food and Drug Administration (FDA) of the IND application for a clinical trial evaluating Nantheia™ A1002N5S, an investigational drug using cannabidiol (CBD) in ANANDA’s proprietary Liquid Structure™ delivery technology as a potential treatment for Social Anxiety Disorder. The National Center for Complimentary and Integrative Health...

GREENWOOD VILLAGE, Colo. and LOS ANGELES, (PRNewswire) ANANDA Scientific Inc., a research focused bio-pharmaceutical company today announced the first patient enrolled in the clinical trial evaluating Nantheia™ ATL5, an investigational drug using cannabidiol (CBD) in ANANDA's proprietary delivery technology as an Adjunctive Treatment for Opioid Use Disorder. (Clinical Trials.gov Identifier: NCT03787628) This trial is being led by principal investigators Edythe London, Ph.D., Distinguished Professor of Psychiatry and Biobehavioral Sciences as well as Molecular and Medicinal...

DENVER, (Newswire.com) ANANDA Scientific Inc., a research-focused bio-pharmaceutical company, today announced that Dennis Wong, President and CEO of Baxco Pharmaceutical Inc, has been appointed to ANANDA Scientific's Board of Directors. "We are very pleased to welcome Dennis to ANANDA's Board of Directors," said John Suh, ANANDA Scientific's Executive Director. "Dennis Wong's experience in leading a state-of-the-art pharmaceutical manufacturing operation is a valuable addition to the ANANDA Scientific Board. He will help guide the company in its pursuit of...

OMAHA, Neb. & GREENWOOD VILLAGE, Colo. -- (BUSINESS WIRE) The University of Nebraska Medical Center (UNMC) and ANANDA Scientific Inc announce a collaboration in a new clinical trial investigating treatment for adults with Post-Traumatic Stress Disorder (PTSD). The trial is being led by principal investigator Mathew Rizzo, M.D., the Reynolds Professor and chair of the UNMC Department of Neurological Sciences and Chief Physician for neurological services at...

GREENWOOD VILLAGE, Co and New York, NY — (BUSINESS WIRE) - ANANDA Scientific Inc., a biotech pharmaceutical company, and NYU Grossman School of Medicine today announced that the first patient has been enrolled in a clinical trial evaluating Nantheia™ A1002N5S, an investigational drug using cannabidiol in ANANDA’s proprietary Liquid Structure™ delivery technology. This trial is evaluating Nantheia™ A1002N5S for Opioid Sparing in the treatment of participants...

GREENWOOD VILLAGE, Colo. & LOS ANGELES , CA — (BUSINESS WIRE) - ANANDA Scientific Inc., (a biotech pharma company) today announced approval by the U.S. Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for the clinical trial evaluating Nantheia™ ATL5, an investigational drug using cannabidiol (CBD) in ANANDA’s proprietary delivery technology as an Adjunctive Treatment for Opioid Use Disorder. The study will...

GREENWOOD VILLAGE, Colo. & NEW YORK (BUSINESS WIRE) - ANANDA Scientific Inc., a biotech pharma company, announced a clinical trial to evaluate Nantheia™ ATL5, an investigational drug using cannabidiol in ANANDA’s proprietary Liquid Structure™ delivery technology for Opioid Use Disorder. An Investigational New Drug (IND) application has been approved by the U.S. Food and Drug Administration (FDA) for this trial. Pre-clinical and initial clinical studies show ANANDA’s...

GREENWOOD VILLAGE, Colo. & LOS ANGELES, CA (BUSINESS WIRE) - ANANDA Scientific Inc., a biotech pharma company, today announced the commencement of a clinical trial to be done in collaboration with the Jane and Terry Semel Institute at David Geffen School of Medicine at UCLA, to evaluate Nantheia™ ATL5, an investigational drug using cannabidiol (CBD) in ANANDA’s proprietary delivery technology as an Adjunctive Treatment for Opioid...

GREENWOOD VILLAGE, Colo. & NEW YORK (BUSINESS WIRE) - ANANDA Scientific Inc., a biotech pharmaceutical company, and NYU Grossman School of Medicine today announced that the first patient has been enrolled in a clinical trial evaluating Nantheia™ A1002N5S, an investigational drug using cannabidiol in ANANDA’s proprietary Liquid Structure™ delivery technology as a treatment for Post-Traumatic Stress Disorder (PTSD) symptoms and Neurocognitive Impairment in patients with PTSD...